A study in the American Heart Journal found that apixaban had the same effect on patients with atrial fibrillation whether or not they had been treated previously with warfarin. The subanalysis of the ARISTOTLE trial found that warfarin-naive patients treated with apixaban spent a median 61.4% time in therapeutic range, while those who had previously received warfarin were in therapeutic range a median 69.1% of treatment time. "In the present prospective comparison, prior [warfarin] exposure did not modify the effect of apixaban relative to warfarin for most key efficacy and safety outcomes," researchers wrote.

Full Story:

Related Summaries